Friday, July 10, 2026

pharma · Phenylketonuria · Amyotrophic Lateral Sclerosis · PTCT

PTC THERAPEUTICS

PTC THERAPEUTICS is a pharma organization headquartered in WARREN, NJ, USA. It trades on NYSE under ticker PTCT. Primary therapeutic focus areas include Phenylketonuria, Amyotrophic Lateral Sclerosis, Cystic Fibrosis, Du

500 Warren Corporate Center Drive, Warren, NJ 07059, US HQ
1998 Founded
1,153 Employees
Public company Type
PTCT · NYSE Ticker
Company details
Status
Public
HQ
500 Warren Corporate Center Drive, Warren, NJ 07059, US
Founded
1998
Employees
1,153
Programs
52
Drugs
21
Patents
149
Clinical program

PTC923-PKU-401

Phase 3 · small molecule · Phenylketonuria

PTC923-PKU-401 for Phenylketonuria is a Phase 3 program (small_molecule) at PTC THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).

← All PTC THERAPEUTICS, INC. projects Phase 3 small molecule active

Internal code PTC923-PKU-401

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
PTC THERAPEUTICS, INC.
Phase
Phase 3
Modality
small_molecule
Indication
Phenylketonuria
Status
active
Trials
1